145 related articles for article (PubMed ID: 31103365)
1. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.
Bernstein DI; Flechtner JB; McNeil LK; Heineman T; Oliphant T; Tasker S; Wald A; Hetherington S;
Vaccine; 2019 Jun; 37(26):3443-3450. PubMed ID: 31103365
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.
Bernstein DI; Wald A; Warren T; Fife K; Tyring S; Lee P; Van Wagoner N; Magaret A; Flechtner JB; Tasker S; Chan J; Morris A; Hetherington S
J Infect Dis; 2017 Mar; 215(6):856-864. PubMed ID: 28329211
[TBL] [Abstract][Full Text] [Related]
3. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.
Flechtner JB; Long D; Larson S; Clemens V; Baccari A; Kien L; Chan J; Skoberne M; Brudner M; Hetherington S
Vaccine; 2016 Oct; 34(44):5314-5320. PubMed ID: 27642130
[TBL] [Abstract][Full Text] [Related]
4. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial.
Van Wagoner N; Fife K; Leone PA; Bernstein DI; Warren T; Panther L; Novak RM; Beigi R; Kriesel J; Tyring S; Koltun W; Lucksinger G; Morris A; Zhang B; McNeil LK; Tasker S; Hetherington S; Wald A
J Infect Dis; 2018 Nov; 218(12):1890-1899. PubMed ID: 29982727
[TBL] [Abstract][Full Text] [Related]
5. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.
Skoberne M; Cardin R; Lee A; Kazimirova A; Zielinski V; Garvie D; Lundberg A; Larson S; Bravo FJ; Bernstein DI; Flechtner JB; Long D
J Virol; 2013 Apr; 87(7):3930-42. PubMed ID: 23365421
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial.
Chandra J; Woo WP; Dutton JL; Xu Y; Li B; Kinrade S; Druce J; Finlayson N; Griffin P; Laing KJ; Koelle DM; Frazer IH
PLoS One; 2019; 14(12):e0226320. PubMed ID: 31846475
[TBL] [Abstract][Full Text] [Related]
7. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
Bernstein DI; Morello CS; Cardin RD; Bravo FJ; Kraynyak KA; Spector DH
Vaccine; 2020 Jan; 38(1):79-89. PubMed ID: 31611098
[TBL] [Abstract][Full Text] [Related]
8. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
9. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A
Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143
[TBL] [Abstract][Full Text] [Related]
10. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
[TBL] [Abstract][Full Text] [Related]
11. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease.
Nesburn AB; Burke RL; Ghiasi H; Slanina SM; Wechsler SL
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1163-70. PubMed ID: 9620075
[TBL] [Abstract][Full Text] [Related]
12. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH
Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141
[TBL] [Abstract][Full Text] [Related]
13. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
[TBL] [Abstract][Full Text] [Related]
14. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
15. Genital shedding of herpes simplex virus among men.
Wald A; Zeh J; Selke S; Warren T; Ashley R; Corey L
J Infect Dis; 2002 Oct; 186 Suppl 1():S34-9. PubMed ID: 12353185
[TBL] [Abstract][Full Text] [Related]
16. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
18. Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
[TBL] [Abstract][Full Text] [Related]
20. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
Harrison CJ; Miller RL; Bernstein DI
Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
